Karim Aouam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Karim Aouam has a total of 227 co-authors. Here are the top co-authors by number of shared publications:
- Amel Chaabane
Fattouma Bourguiba University Hospital of Monastir
41 shared publications Naceur A. Boughattas
Laboratory of Pharmacology, Faculty of Medicine, University of Monastir, Monastir, Tunisia
32 shared publicationsNadia Ben Fredj
Department of Clinical Pharmacology, Fatouma Bourguiba University Hospital, Monastir, Tunisia
24 shared publicationsAlain Reinberg
Unit of Chronobiology, Foundation A. de Rothschild, Paris, France
14 shared publications- Nadia Ben Fredj
Fattouma Bourguiba University Hospital of Monastir
14 shared publications - Zohra Chadli
Department of Pharmacology University Hospital of Monastir, Faculty of Medicine, University of Monastir Monastir Tunisia
14 shared publications
Latest Publications
- 13 February 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (6) , 1929-1933
Amoxicillin‐induced Erythema Scarlatiniforme Desquamativum Recidivans with cross‐reactivity to cefadroxil in a child: A case report and review of literature
Aims: The study's aim is to report the first documented paediatric case of generalized Erythema Scarlatiniforme Desquamativum Recidivans (ESDR), or Féréol‐Besnier disease, induced by amoxicillin and to assess the cross‐reactivity profile to other beta‐lactam antibiotics. Methods: An 8‐year‐old boy with a history of recurrent episodes of diffuse, itchy erythema and subsequent lamellar desquamation following amoxicillin/amoxicillin–clavulanic acid intake was assessed. Causality was evaluated based on clinical history, exclusion of infectious and other drug‐related etiologies, skin biopsy and a positive oral provocation test (OPT) with amoxicillin. Cross‐reactivity to other beta‐lactams was assessed using OPTs with phenoxymethylpenicillin, oxacillin, and cefadroxil. Causality was scored using the Naranjo probability scale. Results: The temporal relationship, resolution after drug withdrawal, and a positive amoxicillin OPT confirmed the diagnosis of amoxicillin‐induced generalized ESDR. The Naranjo score was 8, classifying the reaction as ‘probable’ triggered by amoxicillin. Intradermal and patch tests to amoxicillin–clavulanic acid were negative. The OPTs for phenoxymethylpenicillin and oxacillin were negative. However, the OPT with cefadroxil yielded a positive reaction at the second step (one fourth of the daily dose), indicating a selective aminopenicillin–aminocephalosporin cross‐reactivity. Conclusions: This case establishes the first report of generalized ESDR triggered by amoxicillin in a paediatric patient. It emphasizes a unique pattern of drug hypersensitivity, characterized by cross‐reactivity to cefadroxil and tolerance to other tested penicillins (phenoxymethylpenicillin and oxacillin). It is essential to conduct a complete allergy work‐up, which includes OPTs, to conduct a customized cross‐reactivity assessment. This assessment is essential for the safe guidance of future therapeutic decisions in patients with drug‐induced ESDR.
- 13 February 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (6) , 1929-1933
Amoxicillin‐induced Erythema Scarlatiniforme Desquamativum Recidivans with cross‐reactivity to cefadroxil in a child: A case report and review of literature
Aims: The study's aim is to report the first documented paediatric case of generalized Erythema Scarlatiniforme Desquamativum Recidivans (ESDR), or Féréol‐Besnier disease, induced by amoxicillin and to assess the cross‐reactivity profile to other beta‐lactam antibiotics. Methods: An 8‐year‐old boy with a history of recurrent episodes of diffuse, itchy erythema and subsequent lamellar desquamation following amoxicillin/amoxicillin–clavulanic acid intake was assessed. Causality was evaluated based on clinical history, exclusion of infectious and other drug‐related etiologies, skin biopsy and a positive oral provocation test (OPT) with amoxicillin. Cross‐reactivity to other beta‐lactams was assessed using OPTs with phenoxymethylpenicillin, oxacillin, and cefadroxil. Causality was scored using the Naranjo probability scale. Results: The temporal relationship, resolution after drug withdrawal, and a positive amoxicillin OPT confirmed the diagnosis of amoxicillin‐induced generalized ESDR. The Naranjo score was 8, classifying the reaction as ‘probable’ triggered by amoxicillin. Intradermal and patch tests to amoxicillin–clavulanic acid were negative. The OPTs for phenoxymethylpenicillin and oxacillin were negative. However, the OPT with cefadroxil yielded a positive reaction at the second step (one fourth of the daily dose), indicating a selective aminopenicillin–aminocephalosporin cross‐reactivity. Conclusions: This case establishes the first report of generalized ESDR triggered by amoxicillin in a paediatric patient. It emphasizes a unique pattern of drug hypersensitivity, characterized by cross‐reactivity to cefadroxil and tolerance to other tested penicillins (phenoxymethylpenicillin and oxacillin). It is essential to conduct a complete allergy work‐up, which includes OPTs, to conduct a customized cross‐reactivity assessment. This assessment is essential for the safe guidance of future therapeutic decisions in patients with drug‐induced ESDR.
- Open Access
- 8 December 2025
- Published by Springer Nature in BMC Nursing
- Vol. 24 (1) , 1470
Impact of a wellness charter on nursing practice for older adults in Tunisian healthcare centers: a cross-sectional quasi-experimental multicenter study
Wellness, a comprehensive approach to patient care, aims to promote freedom, respect and listening to the patient needs in order to prevent abuse. No previ
- 8 December 2025
- Published by Springer Nature in BMC Nursing
- Vol. 24 (1) , 1470
Open AccessImpact of a wellness charter on nursing practice for older adults in Tunisian healthcare centers: a cross-sectional quasi-experimental multicenter study
Wellness, a comprehensive approach to patient care, aims to promote freedom, respect and listening to the patient needs in order to prevent abuse. No previ
- Open Access
- 31 January 2024
- Published by Wiley
Sweet Syndrome following SARS-CoV-2 CoronaVac vaccine
We reported the 5 th published case of COVID-19 vaccine inducing SS and the first case to be induced by an inactivated SARS-CoV-2 vaccine « CoronaVac ». The short latency time strongly supports the pathogenic role of the vaccine as a cause of SS in our case.
- 31 January 2024
- Published by Wiley
Open AccessSweet Syndrome following SARS-CoV-2 CoronaVac vaccine
We reported the 5 th published case of COVID-19 vaccine inducing SS and the first case to be induced by an inactivated SARS-CoV-2 vaccine « CoronaVac ». The short latency time strongly supports the pathogenic role of the vaccine as a cause of SS in our case.
- 17 July 2023
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 59 (1) , 10-14
Antituberculosis-Drugs Induced DRESS: A Multidrug Hypersensitivity or Drug Hypersensitivity Relapse? A Case Report
DRESS related to first-line antituberculosis drugs (ATD) is a challenging diagnosis. With a long-lasting combined treatment of 4-concomitantly administrated drugs, identification of the culprit drug remains difficult and may expose patients to treatment interruption and affect their outcome. A 42-year-old female, treated with isoniazid, rifampicin, pyrazinamide and ethambutol for multifocal tuberculosis, developed, 40 days later, hyperthermia, facial edema, cervical lymphadenopathy and generalized exanthema. Biological test results revealed eosinophilia, atypical lymphocytes, and liver injury. DRESS was suspected, and ATD were withdrawn. As patch tests for the 4 ATD showed negative results, we decided to reintroduce pyrazinamide, ethambutol and rifampicin separately with a 3-day interval. Pyrazinamide and rifampicin were tolerated. However, after receiving ethambutol, she developed fever and generalized rash, with no biological abnormalities. Since ethambutol was claimed to be the culprit drug, isoniazid was added, and 10 hours later, the patient developed fever, facial edema, generalized rash, eosinophilia and liver injury. This clinical and biological pattern resolved 2 weeks later. This report suggests a hypersensitivity relapse to ethambutol after isoniazid-induced DRESS.
- 17 July 2023
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 59 (1) , 10-14
Antituberculosis-Drugs Induced DRESS: A Multidrug Hypersensitivity or Drug Hypersensitivity Relapse? A Case Report
DRESS related to first-line antituberculosis drugs (ATD) is a challenging diagnosis. With a long-lasting combined treatment of 4-concomitantly administrated drugs, identification of the culprit drug remains difficult and may expose patients to treatment interruption and affect their outcome. A 42-year-old female, treated with isoniazid, rifampicin, pyrazinamide and ethambutol for multifocal tuberculosis, developed, 40 days later, hyperthermia, facial edema, cervical lymphadenopathy and generalized exanthema. Biological test results revealed eosinophilia, atypical lymphocytes, and liver injury. DRESS was suspected, and ATD were withdrawn. As patch tests for the 4 ATD showed negative results, we decided to reintroduce pyrazinamide, ethambutol and rifampicin separately with a 3-day interval. Pyrazinamide and rifampicin were tolerated. However, after receiving ethambutol, she developed fever and generalized rash, with no biological abnormalities. Since ethambutol was claimed to be the culprit drug, isoniazid was added, and 10 hours later, the patient developed fever, facial edema, generalized rash, eosinophilia and liver injury. This clinical and biological pattern resolved 2 weeks later. This report suggests a hypersensitivity relapse to ethambutol after isoniazid-induced DRESS.
- 1 July 2023
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (9) , 2915-2919
An unusual occurrence of autoimmune pancreatitis after gam‐Covid‐Vac (Sputnik V): A case report and literature review
The safety profile of the Sputnik V vaccine is generally reassuring. Nevertheless, an enhanced risk of new‐onset of immune‐mediated diseases has been increasingly reported following the adenoviral‐based Covid‐19 vaccine, including inflammatory arthritis, Guillain‐Barré syndrome, optical neuromyelitis, acute disseminated encephalomyelitis, subacute thyroiditis and acute liver injury as well as glomerulopathy. However, no case of autoimmune pancreatitis has been reported yet. Herein, we describe a case of type I autoimmune pancreatitis that may be due to the Sputnik V Covid‐19 vaccine.
- 1 July 2023
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (9) , 2915-2919
An unusual occurrence of autoimmune pancreatitis after gam‐Covid‐Vac (Sputnik V): A case report and literature review
The safety profile of the Sputnik V vaccine is generally reassuring. Nevertheless, an enhanced risk of new‐onset of immune‐mediated diseases has been increasingly reported following the adenoviral‐based Covid‐19 vaccine, including inflammatory arthritis, Guillain‐Barré syndrome, optical neuromyelitis, acute disseminated encephalomyelitis, subacute thyroiditis and acute liver injury as well as glomerulopathy. However, no case of autoimmune pancreatitis has been reported yet. Herein, we describe a case of type I autoimmune pancreatitis that may be due to the Sputnik V Covid‐19 vaccine.
- 5 November 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (2) , 561-573
Cross‐reactivity between nonsteroidal anti‐inflammatory drugs in fixed drug eruption: Two unusual cases and a literature review
Nonsteroidal anti‐inflammatory drugs (NSAIDs) are among the main causes of fixed drug eruption (FDE). Cross‐sensitivity between chemically unrelated NSAIDs has been rarely described in FDE. We report herein two cases of NSAID‐induced FDE confirmed by oral provocation test (OPT) with a literature review. Case 1 is a 49‐year‐old woman who took mefenamic, naproxen and acetaminophen for lumbago. On the second day, she noticed three erythematous plaques, located in the upper lip, chin and the right hand, which faded spontaneously, leaving residual patches. Three months later, she took mefenamic acid with reactivation of the same plaques. She received naproxen. On the same day, she exhibited a reactivation of lesions with the development of a new one. These lesions have disappeared leaving hyperpigmented sequelae. After negative patch test to naproxen, an OPT was performed with positive reaction, observed on the third day. To establish the cross‐reactivity, she underwent OPTs, which gave positive results to indomethacin, ketoprofen and tiaprofenic acid. Case 2 is a 52‐year‐old woman who presented painful dusky‐red macules, located in the right and left wrists, 24 hours after taking mefenamic acid. She described two similar events that occurred in the past with an undefined drug and piroxicam. Patch tests to lysine acetylsalicylate, mefenamic acid, piroxicam, naproxen and celecoxib were negative. OPTs to the same NSAIDs gave positive results to lysine acetylsalicylate, piroxicam and mefenamic acid. Thirteen case reports, seven case series and one retrospective analysis, including cases with confirmed cross‐reactivity between NSAIDs, were reported in literature. Clinicians should be aware of such phenomenon.
- 5 November 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (2) , 561-573
Cross‐reactivity between nonsteroidal anti‐inflammatory drugs in fixed drug eruption: Two unusual cases and a literature review
Nonsteroidal anti‐inflammatory drugs (NSAIDs) are among the main causes of fixed drug eruption (FDE). Cross‐sensitivity between chemically unrelated NSAIDs has been rarely described in FDE. We report herein two cases of NSAID‐induced FDE confirmed by oral provocation test (OPT) with a literature review. Case 1 is a 49‐year‐old woman who took mefenamic, naproxen and acetaminophen for lumbago. On the second day, she noticed three erythematous plaques, located in the upper lip, chin and the right hand, which faded spontaneously, leaving residual patches. Three months later, she took mefenamic acid with reactivation of the same plaques. She received naproxen. On the same day, she exhibited a reactivation of lesions with the development of a new one. These lesions have disappeared leaving hyperpigmented sequelae. After negative patch test to naproxen, an OPT was performed with positive reaction, observed on the third day. To establish the cross‐reactivity, she underwent OPTs, which gave positive results to indomethacin, ketoprofen and tiaprofenic acid. Case 2 is a 52‐year‐old woman who presented painful dusky‐red macules, located in the right and left wrists, 24 hours after taking mefenamic acid. She described two similar events that occurred in the past with an undefined drug and piroxicam. Patch tests to lysine acetylsalicylate, mefenamic acid, piroxicam, naproxen and celecoxib were negative. OPTs to the same NSAIDs gave positive results to lysine acetylsalicylate, piroxicam and mefenamic acid. Thirteen case reports, seven case series and one retrospective analysis, including cases with confirmed cross‐reactivity between NSAIDs, were reported in literature. Clinicians should be aware of such phenomenon.
- Open Access
- 25 August 2022
- Published by Wiley
Antituberculosis-drugs induced DRESS: A multidrug hypersensitivity or drug hypersensitivity relapse?
A 42-year-old female, treated with isoniazid, rifampicin, pyrazinamide and ethambutol for multifocal tuberculosis, developed, forty days later, hyperthermia, facial edema, cervical lymphadenopathy and generalized exanthema. Biological test results revealed eosinophilia, atypical lymphocytes, thrombocytopenia and liver injury. DRESS was suspected, and four antituberculosis drugs (ATD) were withdrawn. As patch tests for the four ATD showed negative results, we decided to reintroduce pyrazinamide, ethambutol and rifampicin separately with a three-day interval. Pyrazinamide and rifampicin were tolerated by the patient. However, six hours after receiving ethambutol, she developed fever and generalized rash, with no biological abnormalities, which resolved two days later. Since ethambutol was claimed to be the culprit drug, isoniazid was added, and 10 hours later, the patient developed fever, facial edema, generalized rash, eosinophilia and liver injury. This clinical and biological pattern resolved two weeks later. This report suggests a hypersensitivity relapse to ethambutol after isoniazid-induced DRESS in patients treated with first-line ATD.
- 25 August 2022
- Published by Wiley
Open AccessAntituberculosis-drugs induced DRESS: A multidrug hypersensitivity or drug hypersensitivity relapse?
A 42-year-old female, treated with isoniazid, rifampicin, pyrazinamide and ethambutol for multifocal tuberculosis, developed, forty days later, hyperthermia, facial edema, cervical lymphadenopathy and generalized exanthema. Biological test results revealed eosinophilia, atypical lymphocytes, thrombocytopenia and liver injury. DRESS was suspected, and four antituberculosis drugs (ATD) were withdrawn. As patch tests for the four ATD showed negative results, we decided to reintroduce pyrazinamide, ethambutol and rifampicin separately with a three-day interval. Pyrazinamide and rifampicin were tolerated by the patient. However, six hours after receiving ethambutol, she developed fever and generalized rash, with no biological abnormalities, which resolved two days later. Since ethambutol was claimed to be the culprit drug, isoniazid was added, and 10 hours later, the patient developed fever, facial edema, generalized rash, eosinophilia and liver injury. This clinical and biological pattern resolved two weeks later. This report suggests a hypersensitivity relapse to ethambutol after isoniazid-induced DRESS in patients treated with first-line ATD.
- 20 June 2022
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 78 (9) , 1503-1510
DRESS characteristics according to the causative medication
Background To date, no study has identified a clear relationship between drug and a specific clinical presentation of DRESS. Objectives To investigate the particularities of DRESS and analyze the variation of DRESS pattern according to culprit drugs. Methods We analyzed cases of DRESS notified to the Department of Clinical Pharmacology at the University Hospital of Monastir over a 15-year period. The statistical study was performed using the comparative and multivariate analysis. Results DRESS was mostly induced by anticonvulsive agents (27%) followed by allopurinol (26.3%) and antibiotics (24%): For anticonvulsive agents, the occurrence of lymphadenopathy was higher, renal involvement was rare and mild, and positive skin tests were more frequent. The allopurinol group was associated with the patient’s older age and a lower incidence of lymphadenopathy and kidney injury. For antibiotics, eosinophilia rate was lower, time to recovery was shorter, and RegiSCAR score was low. The multivariate analysis showed a link of allopurinol with severe renal impairment, antibiotics with short latency period and low RegiSCAR score, and anticonvulsants with high propensity of positive skin test. Conclusion We report the largest African and south Mediterranean cohort of DRESS and evaluated the usefulness of skin tests in identifying the culprit drug. The prominent finding was that latency period and renal involvement may independently differ according to culprit drugs.
- 20 June 2022
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 78 (9) , 1503-1510
DRESS characteristics according to the causative medication
Background To date, no study has identified a clear relationship between drug and a specific clinical presentation of DRESS. Objectives To investigate the particularities of DRESS and analyze the variation of DRESS pattern according to culprit drugs. Methods We analyzed cases of DRESS notified to the Department of Clinical Pharmacology at the University Hospital of Monastir over a 15-year period. The statistical study was performed using the comparative and multivariate analysis. Results DRESS was mostly induced by anticonvulsive agents (27%) followed by allopurinol (26.3%) and antibiotics (24%): For anticonvulsive agents, the occurrence of lymphadenopathy was higher, renal involvement was rare and mild, and positive skin tests were more frequent. The allopurinol group was associated with the patient’s older age and a lower incidence of lymphadenopathy and kidney injury. For antibiotics, eosinophilia rate was lower, time to recovery was shorter, and RegiSCAR score was low. The multivariate analysis showed a link of allopurinol with severe renal impairment, antibiotics with short latency period and low RegiSCAR score, and anticonvulsants with high propensity of positive skin test. Conclusion We report the largest African and south Mediterranean cohort of DRESS and evaluated the usefulness of skin tests in identifying the culprit drug. The prominent finding was that latency period and renal involvement may independently differ according to culprit drugs.
- 3 June 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (2) , 544-550
Cefotaxime‐induced drug reaction with eosinophilia and systemic symptom in a child with cross‐reactivity to other cephalosporins and cosensitization to teicoplanin
Drug reaction with eosinophilia and systemic symptom (DRESS) is a severe adverse drug‐induced reaction. Commonly related to anticonvulsant and allopurinol, DRESS can affect both adults and children. Cefotaxime is rarely associated with DRESS, especially with children. We report a cefotaxime‐induced DRESS in a child and emphasize the role of allergological work‐up to point out the culprit drug in exploring cross‐reactivity and identifying a possible cosensitization. A 2‐year‐old boy was treated with cefotaxime, vancomycin and metronidazole for acute otomastoiditis. Metronidazole was withdrawn and vancomycin was changed by teicoplanin 10 and 15 days later, respectively. Nineteen days after ongoing cefotaxime and 4 days after teicoplanin intake, the patient developed hyperthermia, a widespread exanthema, facial oedema with neither mucosal involvement nor palpable lymphadenopathy. Biological tests revealed eosinophilia, atypical lymphocytes, mild cytolysis and a high lactate dehydrogenase level. Serological tests for viral and bacterial infections were negative. DRESS was suspected and the 2 antibiotics were withdrawn. Intradermal tests (IDT) were carried out 2 months later with cefotaxime and teicoplanin. They revealed a positive result at 48‐hour reading. To assess cross‐reactivity among β‐lactams, IDT to penicillins (benzylpenicillin, amoxicillin and oxacillin) was performed showing negative results at 48‐hour reading. Nevertheless, IDT to cephalosporins (cefazolin, cefuroxime, ceftazidime and ceftriaxone) displayed positive results at 48‐hour reading. As a result, IDT are of great interest and should be performed to confirm the role of cefotaxime and detect a potential cross‐reactivity with chemically similar drugs and drugs taken before and during the episode of DRESS.
- 3 June 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (2) , 544-550
Cefotaxime‐induced drug reaction with eosinophilia and systemic symptom in a child with cross‐reactivity to other cephalosporins and cosensitization to teicoplanin
Drug reaction with eosinophilia and systemic symptom (DRESS) is a severe adverse drug‐induced reaction. Commonly related to anticonvulsant and allopurinol, DRESS can affect both adults and children. Cefotaxime is rarely associated with DRESS, especially with children. We report a cefotaxime‐induced DRESS in a child and emphasize the role of allergological work‐up to point out the culprit drug in exploring cross‐reactivity and identifying a possible cosensitization. A 2‐year‐old boy was treated with cefotaxime, vancomycin and metronidazole for acute otomastoiditis. Metronidazole was withdrawn and vancomycin was changed by teicoplanin 10 and 15 days later, respectively. Nineteen days after ongoing cefotaxime and 4 days after teicoplanin intake, the patient developed hyperthermia, a widespread exanthema, facial oedema with neither mucosal involvement nor palpable lymphadenopathy. Biological tests revealed eosinophilia, atypical lymphocytes, mild cytolysis and a high lactate dehydrogenase level. Serological tests for viral and bacterial infections were negative. DRESS was suspected and the 2 antibiotics were withdrawn. Intradermal tests (IDT) were carried out 2 months later with cefotaxime and teicoplanin. They revealed a positive result at 48‐hour reading. To assess cross‐reactivity among β‐lactams, IDT to penicillins (benzylpenicillin, amoxicillin and oxacillin) was performed showing negative results at 48‐hour reading. Nevertheless, IDT to cephalosporins (cefazolin, cefuroxime, ceftazidime and ceftriaxone) displayed positive results at 48‐hour reading. As a result, IDT are of great interest and should be performed to confirm the role of cefotaxime and detect a potential cross‐reactivity with chemically similar drugs and drugs taken before and during the episode of DRESS.
- 27 April 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (2) , 536-540
Erythema nodosum induced by Covid‐19 Pfizer‐BioNTech mRNA vaccine: A case report and brief literature review
Erythema nodosum (EN), the most common form of panniculitis, is a reactive inflammation of the subcutaneous fat clinically presented with a sudden onset of painful, erythematous, nodular, subcutaneous lesions, typically localized to the pretibial area. EN is commonly caused by numerous infections (especially beta‐haemolytic streptococcal infections), autoimmune diseases (sarcoidosis), inflammatory bowel conditions and drugs. EN induced by Covid‐19 vaccines is rarely reported. We describe an original clinical observation of a 75‐year‐old woman who presented with EN after receiving the second dose of BNT162b2, an mRNA vaccine.
- 27 April 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (2) , 536-540
Erythema nodosum induced by Covid‐19 Pfizer‐BioNTech mRNA vaccine: A case report and brief literature review
Erythema nodosum (EN), the most common form of panniculitis, is a reactive inflammation of the subcutaneous fat clinically presented with a sudden onset of painful, erythematous, nodular, subcutaneous lesions, typically localized to the pretibial area. EN is commonly caused by numerous infections (especially beta‐haemolytic streptococcal infections), autoimmune diseases (sarcoidosis), inflammatory bowel conditions and drugs. EN induced by Covid‐19 vaccines is rarely reported. We describe an original clinical observation of a 75‐year‐old woman who presented with EN after receiving the second dose of BNT162b2, an mRNA vaccine.